Core Viewpoint - Investors with significant losses in BioAge Labs, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company due to alleged misleading statements regarding clinical trials and safety concerns [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that BioAge failed to disclose potential liver transaminitis from previous clinical Phase 1 trials and preclinical toxicology studies [3]. - It is claimed that there were safety concerns with the ongoing STRIDES clinical trial that were not communicated to investors [3]. - The company allegedly overstated the likelihood of completing the STRIDES study and the potential of a second Phase 2 clinical trial involving azelaprag and semaglutide for treating obesity in individuals aged 18 and older [3]. - Defendants' positive statements about the company's business and prospects were said to be materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in BioAge Labs, Inc. are encouraged to contact the Law Offices of Howard G. Smith before March 10, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals may retain counsel of their choice or remain absent members of the class action without taking any immediate action [5].
BioAge Labs, Inc. (BIOA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit